Iressa and Nosebleed - a phase IV clinical study of FDA data

Summary:

Nosebleed is reported as a side effect among people who take Iressa (gefitinib), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Carboplatin, and have Lung neoplasm malignant.

The phase IV clinical study analyzes which people have Nosebleed when taking Iressa. It is created by eHealthMe based on reports of 10,081 people who have side effects when taking Iressa from the FDA, and is updated regularly.

What is Iressa?

Iressa has active ingredients of gefitinib. eHealthMe is studying from 10,102 Iressa users. Check the latest studies of Iressa.

What is Nosebleed?

Nosebleed (bleeding from nose) is found to be associated with 2,074 drugs and 3,093 conditions by eHealthMe. Check the latest studies of Nosebleed.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 03, 2026

10,081 people reported to have side effects when taking Iressa.
Among them, 55 people (0.55%) have Nosebleed.

Among these 55 people:

How long have people been on Iressa when they have Nosebleed? *

What is the gender of people who have Nosebleed when taking Iressa? *

female: 54.55 %
male: 45.45 %

What is the age of people who have Nosebleed when taking Iressa? *

What are other drugs people take besides Iressa? *

What are other side effects people have besides Nosebleed? *

Rashes (redness): 13 people, 23.64%
Acne (skin problems that cause pimples): 11 people, 20.00%
Dyspnea (difficult or laboured breathing): 8 people, 14.55%
Itching: 8 people, 14.55%
Malignant Neoplasm Progression (cancer tumour came back): 8 people, 14.55%
Drug Ineffective: 8 people, 14.55%
Anaemia (lack of blood): 8 people, 14.55%
Fever: 7 people, 12.73%
Dry Skin: 7 people, 12.73%
Skin Exfoliation (removal of the oldest dead skin cells): 7 people, 12.73%

What are the existing conditions these people have? *

Lung Neoplasm Malignant (cancer tumour of lung): 15 people, 27.27%
Lung Cancer - Non-Small Cell (lung cancer): 14 people, 25.45%
Lung Adenocarcinoma (a form of non-small cell lung cancer): 13 people, 23.64%
Gastric Ulcer (stomach ulcer): 6 people, 10.91%
High Blood Pressure: 3 people, 5.45%
Neoplasm Malignant (cancer tumour): 3 people, 5.45%
Stable Angina (a constant chest pain): 2 people, 3.64%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 2 people, 3.64%
Cardiac Failure: 2 people, 3.64%
Shoulder Pain: 2 people, 3.64%

* Approximation only. Some reports may have incomplete information.

Do you take Iressa and have Nosebleed?

- Check whether Nosebleed is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Iressa:

Iressa (10,102 reports)

Nosebleed treatments and more:

Nosebleed (92,075 reports)

Browse all side effects of Iressa:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Nosebleed:

Nosebleed (2,074 drugs)

Browse all the conditions that are associated with Nosebleed:

Nosebleed (3,093 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on gefitinib (the active ingredients of Iressa) and Iressa (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.